-

Exactech Announces FDA 510(k) Clearance for Advanced Activit-E Knee Replacement Polyethylene

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced 510(k) clearance from the U.S. Food and Drug Administration for its new, advanced Activit-E™ polyethylene for the Truliant® knee replacement system.

“After years of research and development in polyethylene, Activit-E represents a breakthrough achievement for Exactech,” said Adam Hayden, CMO and SVP, Large Joints Business Unit at Exactech. “It is the next generation of highly crosslinked polyethylene with vitamin E antioxidant that is intended to further our primary goal of providing immense benefits to our patients.”

Activit-E brings an optimized balance of material strength and toughness through chemically crosslinked polyethylene, while eliminating the need for gamma irradiation technology used in previous generations of polyethylene. The material is designed to maintain active oxidative resistance and long-term, high-performance, including strength and stabilization.

This new generation polyethylene is the latest, first-of-a-kind innovation by Orhun Muratoglu, Ph.D., Director of the Harris Orthopaedic Laboratory at Massachusetts General Hospital in Boston. Muratoglu invented the first crosslinked polyethylene, and the first of multiple generations of vitamin E, antioxidant polyethylene for leading orthopaedic companies.

“We replaced gamma radiation crosslinking with peroxide crosslinking and stabilized the poly with vitamin E to provide strength, flexibility, and toughness where it is needed most: total knee arthroplasty. This technology also addressed the looming shortage of gamma radiation for crosslinking, ensuring that patients will continue to benefit from the clinically proven advantages of highly crosslinked polyethylene in total joints,” said Muratoglu.

The first products for Activit-E will launch in the beginning of Q3 2023 for select U.S. customers. Global expansion will begin in 2024.

About Exactech

Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and Twitter. With Exactech by your side, you’ve got EXACTLY what you need.

Contacts

Media Contact
Morgan Lee
Senior Marketing Communications Manager
media@exac.com

EXACTECH INC.

Details
Headquarters: Gainesville, Fla.
Website: www.exac.com
CEO: Darin Johnson
Employees: 800
Organization: PRI

Release Versions

Contacts

Media Contact
Morgan Lee
Senior Marketing Communications Manager
media@exac.com

More News From EXACTECH INC.

Exactech Announces FDA 510(k) Clearance of the World’s First Surgical Navigation for Total Ankle Replacement

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced its subsidiary, BlueOrtho, has received 510(k) clearance from the Food and Drug Administration for ExactechGPS® Ankle, the world’s first surgical navigation system for total ankle arthroplasty (TAA). GPS Ankle is a first-of-its-kind technology, which connects the preoperative plan with real-time intraoperative instrument g...

Exactech Publishes New Machine Learning Research That Evaluates Fairness and Accuracy of AI Predictions

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, reports a new study1 that demonstrates its machine learning clinical decision support tool, Predict+™, creates fair and accurate outcomes predictions for shoulder arthroplasty patients of different ethnicity, sex and age. The study, the first of its kind in orthopaedics, has just been published in the Journal of Shoulder and Elbow...

Exactech AI Platform Surpasses 100,000 Joint Replacement Surgeries Worldwide

GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today its Active Intelligence® (AI) platform surpassed more than 100,000 total joint replacement surgeries across the globe. “We are proud to reach this incredible milestone of more than 100,000 patients with the support of our surgeon partners worldwide,” said Exactech CEO Darin Johnson. “As a leader in orthopaedic innov...
Back to Newsroom